Publikationen in Zusammenarbeit mit Forschern von Universitat Autònoma de Barcelona (18)

2024

  1. Correction to: Detection of kinase domain mutations in BCR::ABL1 leukemia by ultra-deep sequencing of genomic DNA (Scientific Reports, (2022), 12, 1, (13057), 10.1038/s41598-022-17271-3)

    Scientific Reports

  2. Critical review of clinical data and expert-based recommendations for the use of bosutinib in the treatment of chronic myeloid leukemia

    Frontiers in Oncology, Vol. 14

  3. Hepatotoxicity as dose-limiting toxicity of the combination of bosutinib and atezolizumab in patients with chronic myeloid leukemia. Results of the ZEROLMC study

    Annals of Hematology

  4. Impact of somatic gene mutations on the risk of thrombosis in myelofibrosis

    Leukemia

  5. Integrating AIPSS-MF and molecular predictors: A comparative analysis of prognostic models for myelofibrosis

    HemaSphere

  6. ROP-ET: a prospective phase III trial investigating the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythemia patients with limited treatment options

    Annals of Hematology, Vol. 103, Núm. 7, pp. 2299-2310

  7. The prognostic impact of non-driver gene mutations and variant allele frequency in primary myelofibrosis

    American Journal of Hematology

2023

  1. Toxicity of Asciminib in Real Clinical Practice: Analysis of Side Effects and Cross-Toxicity with Tyrosine Kinase Inhibitors

    Cancers, Vol. 15, Núm. 4

2022

  1. Breakthrough infections in MPN-COVID vaccinated patients

    Blood Cancer Journal

  2. Detection of kinase domain mutations in BCR::ABL1 leukemia by ultra-deep sequencing of genomic DNA

    Scientific Reports, Vol. 12, Núm. 1

  3. Real-world analysis of main clinical outcomes in patients with polycythemia vera treated with ruxolitinib or best available therapy after developing resistance/intolerance to hydroxyurea

    Cancer, Vol. 128, Núm. 13, pp. 2441-2448

  4. Second versus first wave of COVID-19 in patients with MPN

    Leukemia

  5. Tyrosine kinase inhibitor dose reduction during the management ofaccelerated phase chronic myeloid leukemia

    Leukemia Research

2021

  1. Among classic myeloproliferative neoplasms, essential thrombocythemia is associated with the greatest risk of venous thromboembolism during COVID-19

    Blood Cancer Journal, Vol. 11, Núm. 2

2020

  1. Predicting Survival after Allogeneic Hematopoietic Cell Transplantation in Myelofibrosis: Performance of the Myelofibrosis Transplant Scoring System (MTSS) and Development of a New Prognostic Model

    Biology of Blood and Marrow Transplantation, Vol. 26, Núm. 12, pp. 2237-2244

2019

  1. Immediate effects of dasatinib on the migration and redistribution of naïve and memory lymphocytes associated with lymphocytosis in chronic myeloid leukemia patients

    Frontiers in Pharmacology, Vol. 10

2018

  1. Clinical characteristics, prognosis and treatment of myelofibrosis patients with severe thrombocytopenia

    British Journal of Haematology

  2. Prognostic risk models for transplant decision-making in myelofibrosis

    Annals of Hematology, Vol. 97, Núm. 5, pp. 813-820